Most Read Articles
Pearl Toh, 3 days ago
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Audrey Abella, 5 days ago
Extremes of sleep duration (≤5 or ≥10 hours/day), which is a known mortality risk factor in the general population, may increase absolute mortality in adults with type 2 diabetes (T2D), a prospective study has shown.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Roshini Claire Anthony, 12 Oct 2020

Insulin icodec, an in-development basal insulin analogue administered once weekly, was as effective as once-daily insulin glargine in patients with type 2 diabetes (T2D) insufficiently controlled with metformin with or without a DPP-4* inhibitor, according to a phase II trial presented at EASD 2020.

High LDL-C levels up incidence of cardiovascular events after PCI

27 Sep 2020

Increased levels of low-density lipoprotein cholesterol (LDL-C) appear to boost the incidence of late cardiovascular events following percutaneous coronary intervention (PCI), a study has found.

“After PCIs, patients remain at high risk of developing late cardiovascular events,” the investigators said. “Although controlling LDL-C may improve outcomes after PCI, practice guidelines do not have specific recommendations on LDL-C management for this subgroup.”

This study evaluated LDL-C testing and levels after PCIs, as well as the association between LDL-C and longer-term cardiovascular events after PCIs. The investigators included all patients who received their first PCI from 1 October 2011 to 30 September 2014 in Ontario, Canada. Patients who had their LDL-C measured within 6 months after PCI were categorized as follows: <70, 70 to <100, and ≥100 mg/dl.

The primary endpoint was a composite of cardiovascular death, myocardial infarction, coronary revascularization, and stroke through 31 December 2016.

A total of 47,884 patients were included, of whom 52 percent had LDL-C measurement within 6 months of PCI and 57 percent had LDL-C <70 mg/dl.

The rates of cardiovascular events after a median 3.2 years stood at 55.2 per 1,000 person-years for the LDL-C <70 mg/dl group, 60.3 per 1,000 person-years for the 70 to <100 mg/dl group, and 94.0 per 1,000 person-years for the ≥100 mg/dl group.

Compared with LDL-C <70 mg/dl, the adjusted subdistribution hazard ratios for cardiovascular events were 1.17 (95 percent confidence [CI], 1.09–1.26) for 70 to <100 mg/dl and 1.78 (95 percent CI, 1.64–1.94) for ≥100 mg/dl.

“Improved cholesterol management after PCI should be considered to improve the outcomes of these patients,” the investigators said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 3 days ago
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Audrey Abella, 5 days ago
Extremes of sleep duration (≤5 or ≥10 hours/day), which is a known mortality risk factor in the general population, may increase absolute mortality in adults with type 2 diabetes (T2D), a prospective study has shown.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Roshini Claire Anthony, 12 Oct 2020

Insulin icodec, an in-development basal insulin analogue administered once weekly, was as effective as once-daily insulin glargine in patients with type 2 diabetes (T2D) insufficiently controlled with metformin with or without a DPP-4* inhibitor, according to a phase II trial presented at EASD 2020.